작은 분자 조사를 시험관 및 셀 모양을 사용 하 여 사전 mRNA 구조 변화 유도

Executive Industry Relevance

RNA-targeting small molecules require precise structural validation to confirm mechanism of action and de-risk therapeutic hypotheses. In vitro and in-cell SHAPE provide orthogonal, nucleotide-resolution insights into RNA structural changes induced by ligand binding, enabling early-stage target validation and predictive confidence in lead optimization. These methods support go/no-go decisions by distinguishing direct RNA effects from cellular context artifacts, reducing late-stage failure risk in nucleic acid drug discovery.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Quantifies ligand-induced RNA structural changes at single-nucleotide resolution to validate target engagement and mechanism of action.
• Operational Value: Enables rapid, cost-effective screening of small molecule effects on RNA folding without requiring cellular systems.
• Scientific Value: In-cell SHAPE captures RNA structure in native cellular context, preserving RNA-binding protein interactions lost in vitro.
• Operational Value: Supports lead identification by correlating structural perturbations with functional outcomes in disease-relevant pre-mRNA targets like SMN2 exon 7.

Screening & Assay Development

• Scientific Value: Provides quantitative, nucleotide-resolved reactivity profiles that serve as direct readouts for RNA structural dynamics.
• Operational Value: In vitro SHAPE uses PAGE-based detection for short RNAs (<200 nt), enabling low-cost, high-throughput screening campaigns.
• Operational Value: In-cell SHAPE leverages next-generation sequencing to analyze longer RNA targets (~1,000 nt), increasing assay scalability and target coverage.
• Scientific Value: Enables assay standardization through normalized SHAPE reactivity metrics, supporting cross-lab reproducibility and data integration.

Translational & Preclinical Research

• Scientific Value: Confirms structural conservation between in vitro models and cellular RNA, strengthening translational relevance of lead compounds.
• Operational Value: Facilitates mechanistic de-risking by distinguishing direct RNA binding from indirect cellular effects.
• Scientific Value: Supports biomarker development by linking RNA structural changes to splicing outcomes or target modulation in preclinical models.
• Operational Value: Informs preclinical advancement decisions by providing structural evidence of target engagement in disease-relevant tissues.

Pipeline & Workflow Integration

SHAPE methods integrate into the discovery continuum from early target validation through lead optimization to preclinical mechanistic studies, particularly for RNA-targeted therapeutics where structural validation is critical for progression.

• Discovery Biology: Enables hypothesis testing of RNA structural mechanisms and pathway clarification through direct observation of ligand-induced folding changes.
• Screening: Delivers assay-ready, quantitative structural readouts that support reproducible compound evaluation and structure-activity relationship (SAR) mapping.
• Analytics: Generates nucleotide-resolution reactivity data and differential SHAPE profiles that allow teams to quantify structural perturbations and compare compound efficacy.
• Translational Research: Bridges discovery and preclinical work by validating RNA structural effects in cellular contexts, ensuring target relevance beyond reductionist models.
• Enterprise Reuse: Establishes a reusable platform for RNA structural interrogation across multiple targets, modalities, and therapeutic areas.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in target validation by reducing mechanistic ambiguity in RNA-small molecule interactions.
• Operational Value: Enhances reproducibility and standardization through well-defined chemical modification and detection workflows.
• Strategic Value: Improves capital efficiency by enabling early de-risking of RNA targets, reducing investment in false positives.
• Portfolio Impact: Supports risk-adjusted prioritization by providing structural evidence to guide lead selection and advancement decisions.

Implementation Considerations

• Requires expertise in RNA biochemistry, radiolabeling safety protocols, and nucleic acid handling for in vitro SHAPE.
• Dependent on access to phosphorimaging equipment, polyacrylamide gel electrophoresis systems, and scintillation counters for radiolabeled detection.
• Necessitates cross-team standardization of RNA folding conditions, SHAPE reagent handling, and data analysis pipelines for reproducible results.
• In-cell SHAPE requires adaptation to cellular permeability, toxicity, and fixation protocols when extending to primary or disease-relevant cell lines.
• Practical limitations include RNA length constraints (~200 nt for in vitro PAGE, ~1,000 nt for in-cell NGS) and potential artifacts from overexpression systems or incomplete ligand equilibration.

Biopharma FAQs